Fármaco de fácil acceso y bajo costo reduce el riesgo de muerte en pacientes graves de coronavirus, suponiendo una nueva esperanza en la lucha contra el COVID19
Luego de unos estudios realizados en la Universidad de Oxford, se concluyó que el Fármaco de fácil acceso y bajo costo reduce el riesgo de muerte en pacientes graves de coronavirus, esto supone una nueva esperanza en la lucha contra el COVID-19
:quality(75)/cdn.jwplayer.com/v2/media/Wit3VgMz/poster.jpg)
:quality(75)/dvgnzpfv30f28.cloudfront.net/06-18-2020/t_ef6cfdf1d2d5445ea340a16d31899cce_name_captura_dexametasona.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ymx43Kre/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X4VBIZZSUJGXBGIJOXH57ZBV3E.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/QxMVfmg2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/3RWZ3FCv/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/4TJYRXpA/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/VYBtNakX/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/o1KPg1hs/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/5BKH5F7JQZCE7IG6XT3WGX5GAY.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/OYRFCZKACRGHJMZRGSMR7XW2L4.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/sZx0DQw9/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/2ZFzjnqS/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Wit3VgMz/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/ymx43Kre/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X4VBIZZSUJGXBGIJOXH57ZBV3E.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/QxMVfmg2/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/6K6E3NMMJJARVG27ISGAQLXPBQ.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/E5G5HWYWUNHFDHML3RA3HBN6BI.png)
:quality(75)/cdn.jwplayer.com/v2/media/DnqOfjf2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Qu9HnWcU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/koNs9MA2/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/6bLTGi5d/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/KgeU8b6Q/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/a6mwPQ4X/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/X3PAJUVAAFHRXHUYV5TON7UAAY.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yksVgSj8/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/wXUo9jVU/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/nu9nKgwG/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/c0S03whF/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/azLadx4o/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/FQ5XSTUGQ5DI3DYDC3MUSLQL6A.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/9a1H4G0a/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/yOEdb2ys/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/JDVYxTbd/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/LIy1dI2W/poster.jpg)
:quality(75)/cdn.jwplayer.com/v2/media/Xv8iJGpA/poster.jpg)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/JW2JBE7IBZEY5NR2VH4KVTPGZ4.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/42WZKDIDGVA6VKQDF75376W2CA.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/ENCJ6JEIFZHT5E6UXK3KZ5RCUU.png)
:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/UZ27WLDNBFBCPCMLG42DQCNJYA.png)